The following criteria is provided for health care professionals.

Inclusion Criteria:

• Symptomatic multiple myeloma requiring treatment
• Received at least two cycles of any regimen as initial systemic therapy for multiple myeloma and are within 2-12 months of the first dose of initial therapy
• At least 18 years of age
• Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved, peripheral blood stem cell collection containing at least 2 × 10^6 CD34+ cells/kg based on patient body weight.
• Adequate organ function as measured by:
  • Cardiac function: Left ventricular ejection fraction at rest ≥40%
  • Hepatic function: Bilirubin ≤2 × ULN and aspartate amino transferase/alanine amino transferase (AST/ALT) ≤3 × ULN
  • Renal function: Creatinine clearance ≥40 mL/minute (measured or calculated/estimated)
  • Pulmonary function: Carbon monoxide diffusing capacity (DLCO; corrected for hemoglobin [Hgb]), forced expiratory volume in 1 second (FEV1), forced expiratory vital capacity (FVC) ≥50% of predicted value
  • Oxygen saturation ≥92% on room air
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
• Able to understand and willing to sign an IRB-approved written informed consent document

Exclusion Criteria:

• Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior to ASCT
• Prior stem cell transplant (autologous or allogeneic)
• Smoldering MM not requiring therapy
• Plasma cell leukemia
• Systemic amyloid light chain amyloidosis
• Active bacterial, viral, or fungal infection
• Seropositive for human immunodeficiency virus (HIV)
• Known, active hepatitis A, B, or C Infection
• Pregnant or breastfeeding.
• Receiving other concurrent anticancer therapy (including chemotherapy, radiation, hormonal treatment, or immunotherapy, but excluding corticosteroids) within 7 days prior to the ASCT or planning to receive any of these treatments prior to the last study visit on Day +100.
• Hypersensitive or intolerant to any component of the study drug(s) formulation
• Receiving growth factors (filgrastim, XM02-filgrastim, peg-filgrastim, plerixafor, etc) or undergoing apheresis < 14 days prior to the start of treatment on protocol (Day -7).